Thymopentin versus placebo in moderate-to-severe atopic dermatitis
Randomized study in people · 1990
- What was studied
- 100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.
- Main finding
- Itch improved at week six · 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).
Reported findings and study design
Reported findings
Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.
Population or model 100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.
Dose, route and schedule
Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.
Protocol source ↗ · Original report, including the pruritus and safety results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Itch improved at week six | 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02). | |
| Itch improved by at least two grades | 11/47 versus 2/45 (p=0.01). | |
| Affected body area | Relative decline of 17% versus 4% (p=0.04). Overall severity also favored thymopentin (p=0.04). | |
| Adverse experiences | 14/48 versus 10/52 reported an adverse experience. The between-group difference was not statistically significant. |
Six-week pruritus results
| Outcome | Thymopentin (n=47) | Placebo (n=45) | Reported p |
|---|---|---|---|
| Any improvement | 31 (66%) | 18 (40%) | 0.02 |
| Improvement of at least two grades | 11 | 2 | 0.01 |
| Worsening | 4 | 3 | — |
More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.
Source details
Original report, including the pruritus and safety results.
Sources checked
Added to the library
Citation
D. Y. Leung, R. L. Hirsch, L. Schneider, C. Moody, R. Takaoka, S. H. Li, L. A. Meyerson, S. G. Mariam, G. Goldstein, J. M. Hanifin. Thymopentin versus placebo in moderate-to-severe atopic dermatitis Journal of Allergy and Clinical Immunology 85(5), 927–933
Study source ↗ · DOI 10.1016/0091-6749(90)90079-J · Bibliography entry · Link to this summary